Alcon (ALC) vs STAAR Surgical (STAA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alcon (ALC) has outperformed STAAR Surgical (STAA) over the past year, losing 3.0% versus a loss of 13.5%. Over five years, ALC leads with a -4.6% price change compared with -75.1% for STAA. Alcon is the larger company by market cap ($35.70 billion vs $1.22 billion), about 29.4 times the size.
On valuation, Alcon trades at a lower forward P/E (19.1x vs 21.4x for STAAR Surgical). Alcon pays a dividend yielding 0.48%, while STAAR Surgical does not currently pay one. Alcon converts more of its revenue into profit, with a net margin of 9.4% versus -33.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALC | STAA |
|---|---|---|
| Share price | $74.31 | $24.22 |
| Market cap | $35.70B | $1.22B |
| 1-day change | -0.26% | -3.24% |
| YTD return | -5.71% | +4.89% |
| 1-year return | -3.00% | -13.50% |
| 5-year return | -4.62% | -75.08% |
| P/E ratio (TTM) | 54.24 | — |
| Forward P/E | 19.05 | 21.39 |
| EPS (TTM) | $1.37 | $0.01 |
| Dividend yield | 0.48% | 0.00% |
| Annual dividend | $0.353 | $0.00 |
| Revenue (latest FY) | $10.40B | $239.44M |
| Revenue growth (YoY) | +4.94% | -23.72% |
| Net income (latest FY) | $980.00M | $-80.45M |
| Gross margin | 55.24% | 76.19% |
| Operating margin | 13.08% | -38.30% |
| Net margin | 9.42% | -33.60% |
| 52-week high | $87.64 | $35.87 |
| 52-week low | $61.84 | $15.59 |
| Distance from 52-week high | -15.21% | -32.48% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +9.37% | +17.92% |
| Average volume | 2.01M | 835.89K |
| Shares outstanding | 480.40M | 50.20M |
| Employees | 25,000 | 921 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alcon is about 29.4 times larger than STAAR Surgical by market value ($35.70B vs $1.22B).
- ALC has outperformed STAA by 10.5 percentage points over the past year.
- Alcon is more profitable, keeping 9.4 cents of every revenue dollar as net income versus -33.6 cents for STAAR Surgical.
- Alcon grew revenue faster in its latest fiscal year (+4.94% vs -23.72%).
About Alcon
ALC stock →Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide.
Health Care · Ophthalmic Goods · 25,000 employees
About STAAR Surgical
STAA stock →STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Health Care · Ophthalmic Goods · 921 employees
ALC vs STAA FAQ
Which is bigger, Alcon or STAAR Surgical?
Alcon (ALC) is larger, with a market capitalization of $35.70B compared with $1.22B for STAAR Surgical (STAA).
Which stock has performed better over the past year, ALC or STAA?
ALC returned -3.00% over the past 12 months, compared with -13.50% for STAA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Alcon or STAAR Surgical?
Alcon pays a dividend yielding 0.48%, while STAAR Surgical does not currently pay a regular dividend.
Are Alcon and STAAR Surgical in the same industry?
Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.